நிறுவனம் ஆஃப் மூலக்கூறு தொற்று உயிரியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novel platform has potential to detect many disease-related biomarkers in just one test Most conventional molecular diagnostics usually detect only a single disease-related biomarker. Great examples are the PCR tests currently used to diagnose COVID-19 by detecting a specific sequence from SARS-CoV-2. Such so-called singleplex methods provide reliable results because they are calibrated to a single biomarker. However, determining whether a patient is infected with a new SARS-CoV-2 variant or a completely different pathogen requires probing for many different biomarkers at one time. Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius Maximilians University (JMU) in Würzburg have now paved the way for a completely new diagnostic platform with LEOPARD. It is a CRISPR-based method that is highly multiplexable, with the potential to detect a variety of disease-related biomarkers in just one test.

Oliver kurzaiCynthia sharmaEmily hendersonInstitute of molecular infection biologyResearch centerHelmholtz instituteHelmholtz centerInfection researchInstitute of hygieneJulius maximilians universityInfection research in braunschweigChase beiselProfessor cynthia sharmaMolecular infection biologyMolecular infectionInfection diseases